Howard B. Lieberman, Ph.D.

Professor of Radiation Oncology
Professor of Environmental Health Sciences

Department of Radiation Oncology, Center for Radiological Research

Dept. Environmental Health Sciences, Mailman School of Public Health

Contact Information: 

Center for Radiological Research
630 West 168th Street
VC 11-219/220
New York, NY 10032

Telephone: (212) 305-9241
Fax: (212) 305-3229



BS, Brooklyn College, 1977
PhD, Rutgers University, 1982
Postdoctoral Fellow, Yale University, 1986


My laboratory is devoted to understanding molecular aspects of radioresistance, chemoresistance and regulation of cell cycle progression in human, mouse and yeast cells. We are especially interested in understanding mechanisms of carcinogenesis and the basis for radiation-induced bystander effects; that is the phenomenon where cells neighboring those directly “hit” by radiation demonstrate phenotypes similar to irradiated cells. We focus on the role of the evolutionarily conserved, multifunctional gene called Rad9 in these processes.  

Selected Activities

Member, Radiation Therapeutics and Biology Study Section, NIH, 2011-2013
Associate Editor, Radiation Research, 2009-present
Associate Editor, Journal of Cellular Physiology, 2006-present
Member, Israel Cancer Research Fund Scientific Advisory Board, 2002-present
External reviewer, Joint Center for Radiation Therapy Foundation, Harvard Medical School, 2001-present
Member, NCI Initial Review Group Basic and Preclinical Subcommittee C, 2000-2005
Member (1995-2000), Chairman (1998-2000), Radiation Study Section, NIH


Panigrahi SK, Hopkins KM, Lieberman HB. Regulation of NEIL1 protein abundance by RAD9 is important for efficient base excision repair. Nucleic Acids Res. 2015 May 19;43(9):4531-46. Epub 2015 Apr 14.

Ghandhi SA, Ponnaiya B, Panigrahi SK, Hopkins KM, Cui Q, Hei TK, Amundson SA, Lieberman HB. RAD9 deficiency enhances radiation induced bystander DNA damage and transcriptomal response. Radiat Oncol. 2014 Sep 18;9:206.

Broustas CG, Lieberman HB. RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels. Prostate. 2014 Oct;74(14):1359-70. Epub 2014 Aug 11.

Broustas CG, Lieberman HB.  DNA damage response genes and the development of cancer metastasis.  Radiation Research. 181:111-130, 2014.

Lyndaker AM, Vasileva A, Wolgemuth DW, Weiss RS, Lieberman HB. Clamping down on meiosis.  Cell Cycle. 12:1-11, 2013.

Broustas CG, Lieberman HB.  Commentary in Beyond the Abstract “Rad9 Contributes to Prostate Tumor Progression by Promoting Cell Migration and Anoikis Resistance.”  UroToday. Issue: May 13, 2013.

Vasileva A, Hopkins KM, Wang X, Weissbach MM, Friedman RA, Wolgemuth DJ, Lieberman HB.  The DNA damage checkpoint protein Rad9 is essential for male meiosis in the mouse.  Journal of Cell Science. 126:3927-3938, 2013.

Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B.  PARP Inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.  Carcinogenesis. 34:739-749, 2013.

Azzam EI, de Toledo SM, Harris AL, Ivanov V, Zhou H, Amundson SA, Lieberman HB, Hei TK. Pathobiology of Cancer Regimen-Related Toxicities edited by S. Sonis and D. Keefe; Springer. pp 35-62, 2012.

Broustas CG, Zhu A, Lieberman HB. Rad9 contributes to prostate tumor progression by promoting cell migration and anoikis resistance.  J. Biol. Chem. 287:41324-41333, 2012.

Young EF, Smilenov LB, Lieberman HB, Hall EJ.  Combined haploinsufficiency and genetic control of the G2/M checkpoint in irradiated cells.  Radiat. Res. 177:743-450, 2012.

Broustas CG, Lieberman HB. Contributions of Rad9 to tumorigenesis. J Cell Biochem. 113, 742-751, 2012.

Lieberman HB, Bernstock JD, Broustas CG, Hopkins KM, Leloup C, Zhu A. The role of RAD9 in tumorigenesis. J Mol Cell Biol. 3, 39-43, 2011.

Leloup C, Hopkins KM, Wang X, Zhu A, Wolgemuth DJ, Lieberman HB. Mouse Rad9b is essential for embryonic development and promotes resistance to DNA damage. Dev Dyn. 239, 2837-2850, 2010.

Han L, Hu Z, Liu Y, Wang X, Hopkins KM, Lieberman HB, Hang H. Mouse Rad1 deletion enhances susceptibility for skin tumor development. Mol Cancer. 9, 67, 2010.

Hei TK, Zhou H, Ivanov VN, Hong M, Lieberman HB, Brenner DJ, Amundson SA, Geard CR. Mechanism of Radiation-Induced Bystander Effects: A Unifying Model. J Pharmacy Pharmacol. 60, 943-950, 2008.

Hu Z, Liu Y, Zhang C, Zhao Y, He W, Han L, Yang L, Hopkins KM, Yang X, Lieberman HB, Hang H. Targeted deletion of Rad9 in mouse skin keratinocytes enhances genotoxin-induced tumor development. Cancer Res. 68, 5552-5561, 2008.

Lieberman HB. DNA damage repair and response proteins as targets for cancer therapy. Curr Med Chem. 15, 360-367, 2008.

Zhu A, Zhang CX, Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. Cancer Res. 68, 1267-1274, 2008.

Liu YX, Wang J, Guo J, Wu J, Lieberman HB, Yin Y. DUSP1 Is Controlled by p53 during the Cellular Response to Oxidative Stress. Mol Cancer Res. 6, 624-633, 2008.


Kleiman NJ, David J, Elliston CD, Hopkins KM, Smilenov LB, Brenner DJ, Worgul BV, Hall EJ, Lieberman HB. Mrad9 and atm haploinsufficiency enhance spontaneous and X-ray-induced cataractogenesis in mice. Radiat Res. 168, 567-573, 2007.

Honors and Awards

Distinguished Alumnus Award, The Lay Advocate Program of Brooklyn College, 2007
Elected Fellow, American Association for the Advancement of Science, 2006
NIH Research Career Development Award, 2005
Elliot Osserman Award, Israel Cancer Research Fund, for Distinguished Service, 2002
HOSA Distinguished Service Award - Health Occupations Students of America, 1993